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Targeted insertion of an anti-CD2 
monoclonal antibody transgene 
into the GGTA1 locus in pigs using 
FokI-dCas9
Mark B. Nottle1, Evelyn J. Salvaris2, Nella Fisicaro2, Stephen McIlfatrick1, Ivan Vassiliev1, 
Wayne J. Hawthorne3, Philip J. O’Connell3, Jamie L. Brady4, Andrew M. Lew4,5 &  
Peter J. Cowan  2,6
Xenotransplantation from pigs has been advocated as a solution to the perennial shortage of donated 
human organs and tissues. CRISPR/Cas9 has facilitated the silencing of genes in donor pigs that 
contribute to xenograft rejection. However, the generation of modified pigs using second-generation 
nucleases with much lower off-target mutation rates than Cas9, such as FokI-dCas9, has not been 
reported. Furthermore, there have been no reports on the use of CRISPR to knock protective transgenes 
into detrimental porcine genes. In this study, we used FokI-dCas9 with two guide RNAs to integrate a 
7.1 kilobase pair transgene into exon 9 of the GGTA1 gene in porcine fetal fibroblasts. The modified cells 
lacked expression of the αGal xenoantigen, and secreted an anti-CD2 monoclonal antibody encoded 
by the transgene. PCR and sequencing revealed precise integration of the transgene into one allele of 
GGTA1, and a small deletion in the second allele. The cells were used for somatic cell nuclear transfer to 
generate healthy male knock-in piglets, which did not express αGal and which contained anti-CD2 in 
their serum. We have therefore developed a versatile high-fidelity system for knocking transgenes into 
the pig genome for xenotransplantation purposes.
Transplantation is an important treatment for a number of medical conditions, but the supply of human donor 
material remains a crucial limiting factor. Indeed, the widening gap between waiting list and transplant recipient 
numbers is driving research into the development of alternative sources including pigs (xenotransplantation). 
Genetic modification has long been used in an attempt to increase the compatibility of porcine organs and tissues 
with human recipients. Knockout (KO) of the GGTA1 (α1,3-galactosyltransferase) gene, which is responsible for 
expression of αGal (the major xenoantigen that elicits hyperacute xenograft rejection) protects porcine xenografts 
in pig-to-nonhuman primate (NHP) models1, as does transgenic expression of human regulators of complement2 
and coagulation3. However, long-term xenograft survival in the absence of ongoing immunosuppression remains 
difficult to achieve. To address this and other issues, many additional genetic modifications are currently under 
investigation. We have focused recently on engineering porcine cells to secrete immunomodulatory molecules 
to provide ‘local’ graft-specific immune protection, with the aim of reducing or eliminating the requirement for 
chronic systemic immunosuppression (and consequently its adverse effects). We generated an anti-CD2 mono-
clonal antibody (mAb) named diliximab that binds to T cells from humans, Old World primates and New World 
primates4. As proof of concept, we demonstrated that adenovirus-transduced porcine islets expressing this mAb 
were protected from infiltration by human T cells in a humanized mouse model5. However, transgenic pigs with 
this modification have not yet been produced.
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One of the challenges in xenotransplantation has been the practical difficulty of combining multiple genetic 
modifications, including knockouts and randomly integrated transgenes, in a single donor pig. Recently, how-
ever, the development of gene editing technology has radically improved the capacity to efficiently modify the pig 
genome. Notably, CRISPR/Cas9 has been used to generate multi-KO pigs in a single step6, 7. A potential disad-
vantage of the wild type (WT) Cas9 nuclease is its propensity to introduce off-target mutations8; this produces an 
unknown threat and emotional burden that may be long term. To overcome this problem, newer versions of Cas9 
with higher fidelity have been developed9. FokI-dCas9, which consists of a nuclease-dead Cas9 fused to a subunit 
of the non-specific endonuclease FokI, uses two guide RNAs to direct cleavage between appropriately spaced 
20-nucleotide target sites, and has remarkably higher (>140 fold) specificity than WT Cas910. A similar chimeric 
nuclease, fdCas9, shows on-target efficiency approaching that of WT Cas9 and an absence of activity at known 
WT Cas9 off-target sites11. FokI-dCas9 has been used to generate KO mice12, but its use in pigs has not been 
reported. In addition, the demonstrated utility of the CRISPR system to generate knock-in pigs13–15 (cf. knockout 
pigs) has not yet been applied for xenotransplantation. To address these gaps, we established a FokI-dCas9-based 
protocol to knock-in a potentially protective transgene, encoding the anti-CD2 mAb diliximab, into the GGTA1 
locus of pigs. This “kills two birds with one stone” by eliminating the gene associated with hyperacute rejection 
while introducing an immunomodulatory molecule.
Results
Targeting of GGTA1 in porcine cells using FokI-dCas9. We targeted exon 9 of GGTA1 because it 
encodes the catalytic domain of α1,3-galactosyltransferase. A pair of guide RNAs (GT-3 and GT-4) was designed 
to recognize sites separated by 26 bp (Fig. 1A), centered on a region that has been shown to be accessible to gene 
editing16. The spacing was based on the observation that FokI-dCas9 cleaves optimally with spacer lengths of ~15 
or ~25 bp10. To test correct targeting, WT pig fetal fibroblasts were co-transfected with expression vectors for 
FokI-dCas9, GT-3 and GT-4. Three days after transfection, the cells were harvested, stained for αGal expression, 
and analyzed by flow cytometry. Approximately 20% of the cells were negative for αGal (Fig. 1B), indicating 
biallelic knockout of GGTA1. By comparison, approximately 30% αGal-negative cells were obtained using WT 
Cas9 with a single guide RNA targeted to the same region (Suppl. Fig. 1 and Suppl. Table 1). The target region, 
amplified by PCR of genomic DNA isolated from the unsorted cells, showed fragments of the expected size when 
analyzed using the Surveyor nuclease assay (Suppl. Fig. 2). The amplified target region from the unsorted cells was 
ligated into a cloning vector, and sequencing of one randomly selected clone revealed a 25 bp deletion around the 
expected cleavage site, predicting a significant mutation of the catalytic domain of the α1,3-galactosyltransferase 
protein (Fig. 1C). Together these data demonstrate efficient targeting and cleavage of GGTA1 exon 9 by FokI-
dCas9 guided by GT-3 and GT-4.
Preparation and validation of an anti-CD2 mAb knock-in construct. We designed a 3.6 kb GGTA1 
knock-in ‘backbone’ containing a 1,060 bp 5′ homology arm (including part of intron 8 and exon 9), a neomycin 
resistance cassette flanked by LoxP sites, a multiple cloning site (MCS) followed by a polyadenylation signal, 
and a 740 bp 3′ homology arm (exon 9) (Fig. 2A). Into the MCS, we cloned stepwise the CMV immediate early 
enhancer, the mouse H-2Kb promoter with a hybrid intron2, and the coding regions for the heavy and light chains 
of the anti-CD2 monoclonal antibody diliximab5 (Fig. 2A). Mouse IgG1 Fc has been substituted with human IgG3 
Fc in this antibody5. The heavy and light chain coding regions were linked by a short sequence encoding a furin 
cleavage site fused to the F2A ribosome skip signal17, which together promote efficient mAb production in vivo18. 
The sequence of the donor DNA template is shown in Suppl. Fig. 3.
To test the correct processing and secretion of the mAb, the knock-in construct (Fig. 2A) was stably trans-
fected into COS-7 cells with neomycin selection, and the culture supernatant was harvested after the cells reached 
confluence. Human leukocytes were incubated first with culture supernatant and then with labelled anti-human 
IgG3, and analyzed by flow cytometry. The supernatant of cells transfected with the knock-in construct, but not 
that of cells transfected with vector alone, contained antibody that bound specifically to CD3+ human T cells 
(Fig. 2B), indicating secretion of diliximab.
Generation and characterization of anti-CD2 knock-in pig fetal fibroblasts. WT male pig 
fetal fibroblasts were co-transfected with the anti-CD2 knock-in construct (Fig. 2A) and expression vec-
tors for FokI-dCas9, GT-3 and GT-4. Neomycin selection was applied three days after transfection, and 12 
neomycin-resistant clones were picked three weeks later. 3/12 clones were successfully expanded, and one of 
these (clone #3) tested αGal-negative by flow cytometry (Fig. 3A). Screening of supernatant from the culture of 
clone #3 on human T cells demonstrated the presence of anti-CD2 mAb diliximab (Fig. 3B).
PCR and sequencing of clone #3 genomic DNA confirmed that the knock-in construct was integrated cor-
rectly within exon 9 of GGTA1 (Fig. 3C and Suppl. Fig. 4). PCR with primers designed to detect the FokI-dCas9 
and GT-3/GT-4 expression vectors (Suppl. Table 2) failed to generate products, indicating that these vectors had 
not integrated into the porcine genome. To determine the status of the second GGTA1 allele, the target region was 
amplified from clone #3 genomic DNA using the primers shown in Fig. 1A and sequenced, revealing a deletion 
of 43 bp overlapping the recognition sites of GT-3 and GT-4 (Suppl. Fig. 5B). Together these data indicated that 
one allele of GGTA1 was disrupted by homology-directed repair (HDR) using the knock-in construct as template, 
while the second allele was inactivated by a deletion resulting from non-homologous end-joining (NHEJ).
To demonstrate the versatility of the system, the 2.4 kb coding region in the anti-CD2 knock-in construct 
(Fig. 2A) was replaced by a 3.7 kb cDNA for the human anticoagulant protein thrombomodulin (hTBM)19. Using 
the transfection and selection procedure described above, 240 neomycin-resistant pig fetal fibroblast clones were 
isolated, of which 11 were both αGal-negative and expressed hTBM on the cell surface (Suppl. Fig. 6). One clone 
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(#107) was analyzed further by PCR and sequencing, revealing precise knock-in of the 8.4 kb hTBM transgene 
into one allele of GGTA1 and a 14 bp deletion in the second allele (Suppl. Fig. 5C).
Cloning and analysis of anti-CD2 knock-in pigs. Anti-CD2 mAb knock-in clone #3 was used to gener-
ate pigs by somatic cell nuclear transfer (SCNT). Nine transfers of 90–130 reconstructed one-cell embryos were 
performed, resulting in two pregnancies. One pregnancy was carried to term and produced four live born male 
piglets, of which two died of natural causes shortly after birth. The surviving piglets were healthy and developed 
Figure 1. Targeting of GGTA1 in WT pig fetal fibroblasts using FokI-dCas9. (A) Target region within GGTA1 
exon 9. Green arrows indicate target sites for guide RNAs GT-3 and GT-4. Red arrowheads indicate binding 
sites for primers GTFS-F1 and GTFS-R1, used to amplify the target region after genome editing. (B) Flow 
cytometric analysis of αGal expression (IB4-FITC) on fibroblasts, three days after co-transfection with 
expression vectors for FokI-dCas9, GT-3 and GT-4. A substantial proportion of the co-transfected cells (red 
line) showed a marked reduction in αGal expression compared to control vector-transfected cells (blue line); 
black line, unstained WT fibroblasts. (C) Sequence analysis of the target region, amplified from genomic DNA 
isolated from the pool of co-transfected cells. One clone contained a 25 bp deletion around the predicted 
cleavage site (arrowhead). The predicted amino acid sequences of WT and mutated α1,3-galactosyltransferase 
are shown below the sequence, indicating an altered stretch of 33 residues (italics) and truncation of 85 residues 
in the mutant protein.
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normally (Fig. 4A). PCR of genomic DNA prepared from ear biopsies confirmed correct integration of the trans-
gene in GGTA1 (Fig. 3C). Flow cytometric analysis demonstrated the absence of αGal expression on peripheral 
blood leukocytes (Fig. 4B), and the presence of anti-CD2 mAb diliximab in the sera of the pigs as detected by 
IgG3 (Fig. 4C).
Discussion
We describe here an efficient method for knocking relatively large transgenes (up to 8.4 kb) into the GGTA1 locus 
in pig cells using the high-fidelity FokI-dCas9 system. Our initial experiment showed that FokI-dCas9 used with 
two guide RNAs was capable of rapidly generating a sizeable proportion of biallelic GGTA1 KO pig cells, even in 
the absence of selection. The efficiency of GGTA1 KO (GTKO) using FokI-dCas9 was approximately two-thirds 
that of WT Cas9, similar to what has been previously reported for other loci10. By including a targeting construct 
containing a transgene and an antibiotic selection marker, knock-in clones expressing the transgene could be 
isolated within one month of transfection. The desired genotype was obtained at a sufficient frequency that it 
was not necessary to enrich for KO pig cells, which has previously been done by flow cytometric cell sorting6 
or magnetic bead selection7, 20. The successful expression of two knocked-in constructs (anti-CD2 and hTBM) 
confirmed that exon 9 of GGTA1 is a permissive site for transcription of integrated transgenes21. Molecular anal-
ysis indicated knock-in of the transgenes by HDR at only one allele of GGTA1, with inactivation of the second 
Figure 2. Validation of the anti-CD2 mAb GGTA1 targeting construct. (A) Top, GGTA1 genomic structure. 
Middle, knock-in backbone showing 5′ and 3′ homology arms (5′-HA and 3′-HA), neomycin resistance cassette 
(NeoR), multiple cloning site (MCS), and polyadenylation signal (pA). Into this was cloned (bottom) the 
CMV immediate early enhancer (CMV IE), mouse H-2Kb promoter, intron, and coding regions for the heavy 
and light chains of anti-CD2 mAb diliximab (αCD2-HC and αCD2-LC) linked by a furin cleavage site-F2A 
ribosome skip signal (f2A). The isotype of diliximab is human IgG3. (B) Detection of anti-CD2 mAb diliximab 
secreted by stably transfected COS-7 cells. Human leukocytes were incubated with culture supernatant, 
and mAb binding to CD3+ T cells was detected with anti-human IgG3. Red line, supernatant (S/N) from 
COS-7 cells transfected with the anti-CD2 knock-in construct; blue line, positive control (62.5 ng/ml purified 
diliximab); black line, supernatant from vector-transfected cells.
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allele by NHEJ. This is consistent with the observation that NHEJ is preferred over HDR at FokI-dCas9-mediated 
double-stranded DNA breaks22.
Two healthy male pigs were generated from the anti-CD2 mAb knock-in cells by SCNT. While the technical 
difficulty of SCNT might be viewed as a limitation of the method, the recent generation of GTKO pigs by intra-
cytoplasmic microinjection of CRISPR/Cas9 DNA into zygotes23 suggests that a simpler alternative may be avail-
able. To our knowledge, the 7.1 kb anti-CD2 transgene is the largest CRISPR-mediated knock-in that has been 
taken to the stage of producing viable pigs. Both pigs were GTKO and expressed anti-CD2 in their serum without 
Figure 3. Analysis of pig fetal fibroblast anti-CD2 knock-in clone #3. (A) Absence of αGal expression by 
clone #3 (red line); blue line, WT fibroblasts; black line, unstained WT fibroblasts. (B) Presence of anti-CD2 
mAb diliximab in the supernatant of clone #3 (red line) detected as described in the legend to Fig. 2; blue line, 
positive control (20 ng/ml purified diliximab); black line, supernatant from WT fibroblasts. (C) PCR analysis 
to confirm correct targeting in clone #3 and in two piglets generated from clone #3 by somatic cell nuclear 
transfer. The schematic diagram (top) shows the expected genomic configuration for integration of the knock-in 
construct in GGTA1; the upstream and downstream homology arms (HA) are shown in yellow. Two primer 
pairs (red arrowheads; 5′ = UKI-F3/UKI-R2; 3′ = 117-F/1123-R), each with one primer outside and one primer 
within the targeting construct, were used with genomic DNA isolated from clone #3 fibroblasts (lanes 1), WT 
fibroblasts (lanes 2), two cloned piglets (lanes 3 and 4), and one WT piglet (lanes 5). Clone #3 and both cloned 
piglets generated upstream and downstream products of the expected size (1506 bp, lanes 1, 3 and 4, left hand 
gel; and 947 bp, lanes 1, 3 and 4, right hand gel, respectively), which were confirmed by sequencing. MW, 
molecular weight markers (λ/HindIII + θX174/HaeIII).
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apparent detrimental effects, presumably because the mAb is specific for human and primate CD24, 5 and is not 
expected to deplete pig T cells. The knock-in pigs will be bred with GTKO-CD55-CD59-HT pigs to generate 
donors for our pig-to-baboon neonatal islet xenotransplantation model24. This will allow us to test the hypothesis 
that xenograft-specified expression of diliximab (that recognizes both human and primate CD2) will prolong 
xenograft survival by locally depleting infiltrating recipient T cells. Although we did not measure the frequency of 
off-target mutations, there is already ample evidence to support the greater specificity of FokI-dCas910, 25 and the 
closely related fdCas911 compared to WT Cas9. Furthermore, breeding of the knock-in pigs is expected to dilute 
detrimental off-target mutations, if any.
The GGTA1 knock-in backbone was designed for versatility by incorporating a multiple cloning site to enable 
simple interchange of transgene regulatory elements and/or coding regions. The neomycin resistance cassette is 
flanked by LoxP sites and can be excised using Cre recombinase if desired. In addition, the backbone can be mod-
ified to incorporate a different antibiotic selection marker, potentially enabling simultaneous knock-in of different 
transgenes into the two alleles of GGTA1. The relative ease with which the 8.4 kb hTBM transgene was knocked 
into the pig genome suggests that the upper size limit for HDR using relatively short homology arms (1.06 and 
0.74 kb) has not been reached. We therefore envisage that additional genes can be incorporated into the knock-in 
construct, either as separate transcriptional units or by using 2A for multi-cistronic expression.
Methods
All experiments with animals and human samples were performed in accordance with relevant guidelines 
and regulations. Genetically engineered pigs were generated and used with the approval of the Animal Ethics 
Committee of the University of Adelaide (approval number M-2012-084B), in accordance with the Australian 
Figure 4. Anti-CD2 knock-in pigs. (A) Healthy appearance of the pigs. (B) Absence of αGal expression on 
peripheral blood leukocytes (PBL) (red line); blue line, WT leukocytes; black line, unstained. (C) Presence of 
anti-CD2 mAb diliximab in the serum (diluted 1:50) of a knock-in pig (red line), detected as described in the 
legend to Fig. 2; blue line, positive control (WT pig serum spiked with 200 ng/ml purified diliximab); black line, 
WT pig serum.
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Code of Practice for the Care and Use of Animals for Scientific Purposes (National Health and Medical Research 
Council, 2013). Human blood was drawn from healthy volunteers with informed consent and with the approval 
of the St Vincent’s Hospital Melbourne Human Research Ethics Committee.
Reagents. Unless otherwise specified, chemicals were obtained from Sigma Aldrich (Sydney, Australia), and 
cell culture and molecular biology reagents were obtained from Thermo Fisher Scientific (Scoresby, Australia).
Preparation of knock-in constructs. The 3.58 kb GGTA1 knock-in backbone, including flanking NotI 
sites, was synthesized by GenScript (Piscataway, NJ) and cloned in the vector pUC57. It contained a MCS includ-
ing sites (5′ to 3′) for FseI, AscI and EcoRI. The anti-CD2 mAb and hTBM knock-in constructs were prepared 
in three steps. First, the 0.66 kb CMV immediate early enhancer was amplified by PCR of the vector pCI-Neo 
(Promega, Alexandria, Australia) using FseI-containing primers, and cloned into the FseI site of the knock-in 
backbone. Second, a 2.2 kb PCR product containing a 2.0-kb mouse H-2Kb promoter and a 0.2 kb hybrid intron 
was amplified from a previously described transgenic construct26 using AscI-containing primers, and cloned 
into the AscI site. Finally, an EcoRI fragment encoding either the anti-CD2 mAb diliximab5 (2.4 kb) or hTBM19 
(3.7 kb) was cloned into the EcoRI site. The anti-CD2 EcoRI fragment consisted of the coding regions for the heavy 
and light chains linked by a furin cleavage site/F2A ribosome skip signal, and was synthesized by GenScript. All 
constructs were fully sequenced. NotI, FseI and AscI were obtained from New England Biolabs (Genesearch, 
Arundel, Australia).
Tissue culture. Cells were grown in 5% CO2 at 37 °C. WT male pig fetal fibroblasts (Large White/Landrace) 
were grown in 0.01% gelatin-coated flasks in 50% Dulbecco’s Modified Eagle’s Medium (DMEM), 50% M199, 
10% heat-inactivated fetal calf serum (FCS), penicillin/streptomycin and 5ng/ml bFGF, and used at passage 7. 
COS-7 cells were cultured in DMEM with 10% heat-inactivated FCS.
Transfection. Transfection of WT porcine fetal fibroblasts was performed using an Amaxa 4-D Nucleofector 
using the P3 Nucleofector Kit and the EN150 program (Lonza, Mount Waverley, Australia). 106 cells were trans-
fected with a total of 5 μg of DNA, comprising equal amounts of the expression vectors for FokI-dCas9 (plasmid 
#52970, Addgene, Cambridge, MA) and the single guide RNAs (GenScript), plus/minus the knock-in construct 
(excised from the pUC57 vector using NotI). Three days after transfection, the cells were either harvested for 
analysis or neomycin (G418, 800 μg /ml) was added to select stable transfectants.
Transfection of COS-7 cells was performed using a GenePulser electroporator (Bio-Rad, Gladesville, 
Australia). 5 × 106 cells were transfected with 5 μg of the anti-CD2 mAb knock-in construct at 250 volts and 950 
μFd. Three days after transfection, G418 (800 μg/ml) was added to select stable transfectants. When the trans-
fected cells reached confluence, the culture supernatant was collected for detection of anti-CD2 mAb diliximab 
as described below.
Flow cytometry. For analysis of cell surface expression of αGal or hTBM, cells were stained with 
FITC-conjugated Griffonia simplicifolia I-B4 lectin (IB4) or anti-hTBM clone IA4 (kind gift of Dr Phillip Bird, 
Monash University, Melbourne, Australia), respectively, and analyzed on a FACSCanto II (Becton Dickinson, 
North Ryde, Australia) as described17, 26. Secreted anti-CD2 mAb diliximab was detected as follows using human 
T cells as targets. Leukocytes were isolated from human blood using Ficoll Paque Plus gradients (GE Healthcare, 
Murarrie, Australia). 105 leukocytes were incubated for 1 hr with culture supernatant or serum, or purified dil-
iximab5 as positive control. After washing, the cells were incubated with goat anti-human IgG-biotin (Thermo 
Fisher Scientific, catalog #12-4998-82) and anti-human CD3-FITC (BD Biosciences, North Ryde, Australia; cata-
log #555332) for 30 minutes. The cells were analyzed on the FACSCanto II using CD3+ gating of T cells.
Somatic cell nuclear transfer. Porcine oocyte collection and in vitro maturation in BOMED maturation 
medium were performed as described27, 28. Cell culture before nuclear transfer was performed as described27 
except that cells were dissociated by incubation for 5 min in TrypLE. Nuclear transfer was performed using the 
fusion before activation protocol as described27.
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